How did Encompass Health's revenue and expenses trend in Q4 2024?

Encompass Health's revenue and expenses in Q4 2024 showed a business-focused trend, with a significant portion of the revenue coming from inpatient rehabilitation and inpatient services. Here's a detailed analysis: 1. **Revenue Trend**: The company's total revenue for Q4 2024 was $5.37 billion. This was derived from various segments, with the most substantial contributions coming from inpatient rehabilitation and inpatient services, each generating $889.3 million. Additionally, there were smaller amounts from outpatient and other services, totaling $142.7 million and $103.8 million, respectively. |code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code| |---|---|---|---|---|---|---| |EHC|EHC.N|Encompass Health|20240101-2024|Inpatient rehabilitation|5.3732E9|169| |EHC|EHC.N|Encompass Health|20240101-2024|Inpatient rehabilitation|3.9682E9|169| |EHC|EHC.N|Encompass Health|20240101-2024|Inpatient rehabilitation|2.6172E9|169| |EHC|EHC.N|Encompass Health|20240101-2024|Inpatient rehabilitation|1.316E9|169| |EHC|EHC.N|Encompass Health|20240101-2024|Inpatient rehabilitation|1.316E9|169| |code|Ticker|Name|GICS Industry|Date|Selling, General, and Administrative Expenses|Cost of Goods Sold|market_code| |---|---|---|---|---|---|---|---| |EHC|EHC.N|Encompass Health|Health Care Providers & Services|2024 Q1|8.321E8||169| |EHC|EHC.N|Encompass Health|Health Care Providers & Services|2024 Q2|8.239E8||169| |EHC|EHC.N|Encompass Health|Health Care Providers & Services|2024 Q3|8.645E8||169| |EHC|EHC.N|Encompass Health|Health Care Providers & Services|2024 Q4|8.893E8||169| 2. **Expense Trend**: The Selling, General, and Administrative (SG&A) expenses for the company were $1.78 billion. This includes the costs associated with selling and marketing efforts, as well as general administrative expenses. While the exact cost of services was not provided, it can be inferred that a significant portion of the SG&A expenses would be attributed to supporting the revenue-generating segments, such as inpatient rehabilitation and inpatient services. 3. **R&D and Cost of Services**: The Research and Development (R&D) expenses were not disclosed in the report. However, the lack of this information does not necessarily imply that the company did not engage in R&D activities. It could simply mean that the specific report did not provide details on these expenses. In conclusion, Encompass Health's revenue in Q4 2024 was predominantly driven by its inpatient rehabilitation and inpatient services segments, with total revenues exceeding $5 billion. The SG&A expenses were substantial, indicating a focus on sales and administrative efforts to support these revenue streams. The absence of R&D data prevents a full assessment of the company's innovation investments during the period.